NZ574193A

NZ574193A - Macrolide synthesis process

Info

Publication number: NZ574193A
Application number: NZ574193A
Authority: NZ
Inventors: Fritz Blatter; Meinrad Brenner; Monika Brink; Kerstin Fleischhauer; Guixian Hu; Hans Peter Niedermann; Timo Rager; Tanja Schweisel; Stephan Veit; Ralf Warrass; Heinz-Jorg Wennesheimer
Original assignee: Intervet Int Bv; Microbial Chem Res Found
Priority date: 2006-07-28
Filing date: 2007-07-26
Publication date: 2011-09-30
Also published as: TW200831524A; SI2089408T1; ES2374950T3; BRPI0715642C8; ATE528312T1; CN102875622A; CN102875622B; BRPI0715642B8; RU2450014C2; BRPI0715642A2; BRPI0715642B1; RU2009107167A; TWI397534B

Abstract

Disclosed is a process for making a macrolide compound, or salt thereof, of formula (I). The process comprises the following steps; Reacting tylosin A (or a salt thereof), a piperidinyl compound of formula (II), and formic acid in the presence of a non-polar solvent to form a 20-piperidinyl-tylosin compound, Reacting a 20-piperidinyl-tylosin compound with an acid to form a 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, Reacting a 23-O-mycinosyl-20-piperidinyl-5-O-mycaminosyltylonolide compound with an acid to form a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, Activating a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyltylonolide compound with an activating agent to form an activated compound, and Reacting an activated compound with a piperidinyl compound of Formula (VII).

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 574193 WO 2008/012343 PCT/EP2007/057710 MACROLIDE SYNTHESIS PROCESS CROSS-REFERENCE TO RELATED PATENT APPLICATIONS [1] This patent claims priority to U.S. Provisional Patent Application No. 60/834,067 (filed July 28, 2006); and European Patent Application No. 06118159.0 (filed July 31, 2006). The entire text of both those patent applications is incorporated by reference into this patent. FIELD OF THE INVENTION [2] This invention relates to a method for making macrolides, and, in particular, to a method for making optionally substituted 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide and derivatives thereof, as well as methods of treatment using such macrolides, uses of such macrolides to make medicaments, and methods for making intermediates that, inter alia, may be used to make macrolides. BACKGROUND OF THE INVENTION [3] Macrolides have long been known to be effective for treating infectious diseases in humans, livestock, poultry, and other animals. Early macrolides included 16-membered macrolides such as, for example, tylosin A: See, e.g., U.S. Patent No. 4,920,103 (col. 5, lines 12-38). See also, U.S. Patent No. 4,820,695 (col. 7, lines 1-32) and EP 0103465B1 (page 5, line 3). Over the years, various tylosin derivatives have been developed with the goal of enhancing antibacterial activity and selectivity. [4] Tylosin derivatives include, for example, compounds discussed in U.S. Patent No. 6,514,946 that correspond in structure to Formula (I): WO 2008/012343 PCT/EP2007/057710 2 3 ,,-Y (AAA. ™ 3h 3 r4 ch3 (I)- Here: 5 R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R1, R2, and R3 are each hydrogen; and R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. Such compounds include, for example, 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide, which has the following structure: 10 These compounds, and particularly 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide, are believed to have pharmacokinetic and pharmacodynamic attributes for safe and effective treatment of, for example, pasteurellosis, bovine respiratory disease, and swine respiratory disease. A discussion relating to the use of these compounds to treat livestock and poultry diseases is included in U.S. Patent No. 6,514,946. That discussion is incorporated by 15 reference into this patent. [5] Various approaches for making macrolides have been reported. [6] In EP 0103465B1, for example, Debono et al. discuss various process steps for making compounds within their recited genus. These processes include, for example, the following reduction: ch3 WO 2008/012343 PCT/EP2007/057710 chq chq + hr Here, R, R1, R2, R3, and R4 are defined as various substituents. R, in particular, is defined as a nitrogen-containing ring system that has up to 3 unsaturated or saturated rings that are optionally substituted. Debono et al. report that the preferred reducing agent is a cyanoborohydride, and that sodium cyanoborohydride is "the reducing agent of choice." Debono et al. also state that the solvent for this reaction will normally be an inert polar solvent, such as a C1-C4 alkanol. See page 6, lines 7-14. In a later-filed patent in the same patent family, Debono et al. further discuss reductive amination of various aldehyde compounds (including tylosin) with an amine. Sodium cyanoborohydride and sodium borohydride are cited as suitable reducing agents, and anhydrous methanol is cited as a suitable solvent. See U.S. Patent No. 4,820,695, col. 7, lines 60-68. [7] In U.S. Patent No. 6,664,240, Phan et al. also discuss a reductive amination: h,c 110 O R7 HN R8 H,C OR4 Here, RP2, R4, R7 and R8 are defined as various substituents. R7 and R8, in particular, are each defined as being independent substituents, or, alternatively, as together forming a 3-to 7-member heterocyclic ring. Phan et al. discuss conducting this reaction with a borohydride reagent in an alcohol or acetonitrile solvent. Sodium borohydride and sodium cyanoborohydride are listed as example borohydride reagents; and methanol, ethanol, and isopropanol are listed as example alcohol solvents. See, e.g., col. 15, line 64 to col. 16, line 42; and col. 22, lines 41-49. [8] In EP 0240264B1, Tao et al. also discuss a reductive amination: WO 2008/012343 PCT/EP2007/057710 4 defined as each being independent substituents, or, alternatively, as together forming a heterocyclic ring system having up to 3 optionally substituted rings. Tao et al. report that this reduction may be achieved using formic acid as the reducing agent. Tao et al. further report that the solvent will ordinarily be an inert polar organic solvent. Amyl acetate and acetonitrile are cited as examples of such a solvent. See page 4, line 57 to page 5, line 10. See also, U.S. Patent No. 4,921,947, col. 3, line 62 to col. 4, line 16. [9] In EP 0103465B1, Debono et al. discuss the following hydrolysis reaction: Here, R, R1, R2, and R4 are defined as various substituents. Debono et al. report that this "hydrolysis can be effected using a strong aqueous mineral acid as hydrochloric or sulfuric acid, or a strong organic acid such as /;-tolucncsulfonic acid." See page 7, lines 3-8. In a later-filed patent of the same patent family, Debono et al. further discuss mycarose hydrolysis of C-20-modified derivatives of tylosin, macrocin, and DOMM using "well known" procedures for acidic hydrolysis. See U.S. Patent No. 4,820,695, Col. 8, lines 35-43.

[10] In view of the importance of macrolides in the treatment of a plethora of pathological conditions, there continues to be a need for cost-effective, high-yield processes for making macrolides. The following disclosure addresses this need. SUMMARY OF THE INVENTION [11] This invention relates to processes for making macrolides, and, in particular, optionally substituted 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide and WO 2008/012343 PCT/EP2007/057710 derivatives thereof. Such processes include processes for making the macrolides themselves, as well as processes for making compounds that, inter alia, may be used as intermediates for making various macrolides.

[12] Briefly, this invention is directed, in part, to a process for making a macrolide and salts thereof. The macrolide corresponds in structure to Formula (I): (I)- Here: As to R1, R2, and R3: R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R\R2, andR3 are each hydrogen. As to R4, R5, and R6: R4 and R6 are each methyl, and R5 is hydrogen, R4 and R6 are each hydrogen, and R5 is methyl, or R4, R5, and R6 are each hydrogen.

[13] In some embodiments, the process comprises reacting tylosin (e.g., tylosin A or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent. In these embodiments, the piperidinyl compound of Formula (II) corresponds in structure to: R r R n h (II).

[14] In some embodiments, the process comprises reacting a 20-piperidinyl-tylosin compound with an acid. In these embodiments, the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III): WO 2008/012343 PCT/EP2007/057710 h3C -() o. ch, ch, oh 13 (III).

[15] In some embodiments, the process comprises reacting a 23-O-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound with an acid. In these embodiments, the 23 -O-mycino syl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound corresponds in structure to Formula (IV): r1 ,r2 H3C-0 6, 13 (IV).

[16] In some embodiments, the process comprises activating a 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound with an activating agent to form an activated compound. In these embodiments, the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound corresponds in structure to Formula (V): r1 ,r2 ho' (V). WO 2008/012343 PCT/EP2007/057710 7 The activated compound (also referred to as a "23-L-20-piperidinyl-5-O-mycamino syl-tylono lide compound") corresponds in structure to Formula (VI): r1 And L is a leaving group.

[17] In other embodiments, the process comprises reacting an activated compound of Formula (VI) with a piperidinyl compound of Formula (VII). In these embodiments, the piperidinyl compound of Formula (VII) corresponds in structure to:

[18] In some embodiments, the process comprises a combination of the above embodiments to make a macrolide of Formula (I) or salt thereof.

[19] In some embodiments, the process comprises one or more of the above embodiments to make, for example, an amorphous, crystalline, co-crystalline, or solvate form of the macrolide of Formula (I) or a salt thereof.

[20] This invention also is directed, in part, to a process for making the 20-piperidinyl-tylosin compound of Formula (III) or a salt thereof. In these embodiments, the process comprises reacting tylosin (e.g., tylosin A), the piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent.

[21] This invention also is directed, in part, to a process for making the 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound of Formula (IV) or a salt thereof. In these embodiments, the process comprises reacting the 20-piperidinyl-tylosin compound of Formula (III) with HBr.

[22] This invention also is directed, in part, to a process for making a 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound of Formula (V) or a salt ch3 (VI). h (VII). WO 2008/012343 PCT/EP2007/057710 8 thereof. In these embodiments, the process comprises reacting the 23-0-mycinosyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound of Formula (IV) with an acid.

[23] This invention also is directed, in part, to a process for making an activated compound of Formula (VI) or a salt thereof. In these embodiments, the process comprises 5 activating a 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound of Formula (V) with an activating agent.

[24] This invention also relates to using compounds of Formula (I) (and pharmaceutically acceptable salts thereof) prepared in accordance with this invention in methods for treating a disease, such as pasteurellosis, swine respiratory disease, or bovine 10 respiratory disease. More specifically, this invention is directed, in part, to a method that comprises preparing a compound of Formula (I) (or a pharmaceutically acceptable salt thereof) in accordance with one or more of the above cited methods, and then administering a therapeutically effective amount of the compound or salt to an animal in need of the treatment. This invention also is directed, in part, to using a compound of 15 Formula (I) (or a pharmaceutically acceptable salt thereof) prepared in accordance with this invention to prepare a medicament, particularly a medicament for use in the above treatments.

[25] Further aspects and benefits of Applicants' invention will be apparent to one skilled in the art from reading this specification. 20 DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[26] This detailed description of preferred embodiments is intended only to acquaint others skilled in the art with Applicants' invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its 25 numerous forms, as they may be best suited to the requirements of a particular use. This detailed description and its specific examples, while indicating preferred embodiments of this invention, are intended for purposes of illustration only. This invention, therefore, is not limited to the preferred embodiments described in this specification, and may be variously modified. 30 A. Macrolides That May Be Prepared By This Invention

[27] Compounds that may be prepared by the process of this invention include compounds corresponding in structure to Formula (I): WO 2008/012343 PCT/EP2007/057710 9 Here: R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R1, R2, and R3 are each hydrogen; and R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. In some embodiments, the piperidinyl substituents of Formula (I) are identical, i.e. In some such embodiments, for example, both piperidinyl substituents are piperidine (i.e., R1, R2, R3, R4, R5, and R6 are each hydrogen), such that the compound is 20,23-dipiperidinyl-5 -O-mycamino syl-tylono lide: Such compounds include, for example: WO 2008/012343 PCT/EP2007/057710 Other compounds having identical piperidinyl substituents include: ^ch3 h,c ch, oh , Snd h,c ch, oh ch3 ch3

[28] In some embodiments, the piperidinyl substituents of Formula (I) are not identical, i.e.: R r! R IS DIFFERENT THAN n Compounds having different piperidinyl substituents include: o h,c ch, oh ch, h,c ch3 ch3 oh ch3 ch3 WO 2008/012343 PCT/EP2007/057710 11 ch3 ch3 B. Macrolide Synthesis

[29] This invention may be used to synthesize macrolides from materials generally available in the art. 5 B-l. Preparation of 20-Piperidinyl-Tylosin Compound

[30] In some embodiments, the macrolide synthesis begins by or includes preparing a 20-piperidinyl-tylosin compound, and particularly a compound corresponding in structure to Formula (III): In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen, such that the compound corresponds in structure to: WO 2008/012343 PCT/EP2007/057710 12 h,c h3C-CT O. °' ch3 ch3 oh

[31] The 20-piperidinyl-tylosin compound may be prepared from tylosin A and a piperidinyl compound via a reductive amination reaction using a reducing agent comprising formic acid (or "HCOOH"): o H3C HO H3C-O O. ° ch3 CHO H3C trr> \j''CH1 HOx N OH TH + OH 3 CH3 OH ch3 tylosin A n H piperidinyl reagent I formic acid ch3 20-piperidinyl-tylosin compound Where R1, R2, and R3 are each hydrogen, this reaction is as follows: WO 2008/012343 PCT/EP2007/057710 13 o h3c— ho h3c— ho Tylosin A, piperidinyl compounds, and formic acid are commercially available.

[32] The tylosin A reagent may, for example, be pure (or at least essentially pure) tylosin A. Alternatively, as noted below in Section B-7, the tylosin A reagent may be part of a mixture, such as, for example, a mixture comprising tylosin A as well as one or more tylosin A derivatives, such as tylosin B, tylosin C, and/or tylosin D.

[33] The tylosin A may be in the form of its free base, or, alternatively, in the form of a salt. The tylosin A derivatives likewise are optionally in the form of one or more salts. It is contemplated that a variety of salts may be suitable. In some embodiments, for example, the salt comprises a phosphate salt. In other embodiments, the salt comprises a tartrate salt. In still other embodiments, the salt comprises a citrate or sulfate salt. Further discussion relating to salts may be found below in Section C.

[34] The solvent may comprise one or more solvents. Although the solvent may comprise one or more polar solvents in some embodiments, the solvent preferably instead comprises one or more non-polar solvents. A "non-polar solvent" is a solvent that does not ionize sufficiently to be electrically conductive, and cannot (or at least essentially cannot) dissolve polar compounds (e.g., various inorganic salts), but can dissolve nonpolar compounds (e.g., hydrocarbons and resins). In general, the solvent preferably is non-reactive with the reagents, products, and any other ingredients in the reaction mixture. The solvent may comprise, for example, chloroform (or "CHCI3"); tetrahydrofuran (or "THF"); dichloromethane (or "CH2CI2" or "DCM" or "methylene chloride"); carbon tetrachloride (or "CCU"); ethyl acetate (or "CH3COOC2H5"); diethyl ether (or "CH3CH2OCH2CH3"); WO 2008/012343 PCT/EP2007/057710 14 cyclohexane (or "C6H12"); or aromatic hydrocarbon solvents, such as benzene (or "C6H6"), toluene (or "C6H5CH3"), xylene (or "C6H4(CH3)2" or "dimethylbenzene" (including 1,3-dimethylbenzene (or "m-xylene"), 1,2-dimethylbenzene (or "o-xylene"), or 1,4-dimethylbenzene (or "/^-xylene")), ethylbenzene, or mixtures thereof (e.g., mixtures of m-5 xylene, o-xylene,/^-xylene, and/or ethylbenzene). In some embodiments, the solvent comprises dichloromethane, chloroform, or ethyl acetate. In other embodiments, the solvent comprises xylene. In still other embodiments, the solvent comprises toluene. In some such embodiments, toluene is particularly preferred because of its ease of use at typical reaction temperatures. 10 [35] In some embodiments, the solvent comprises a mixture of solvents. In some such embodiments, for example, the solvent comprises a mixture of toluene and DCM. Here, the toluene/DCM ratio may be, for example, from about 1:1 to about 100:1, or from about 5:1 to about 8:1 (v/v). In some of these embodiments, the ratio is, for example, about 8:1 (v/v). In others, the ratio is, for example, about 5.3:1 (v/v). 15 [36] To perform the amination, the tylosin A reagent, piperidinyl compound, formic acid (or a source of formic acid), and solvent normally are charged to a reactor and mixed. These ingredients may generally be charged to the reactor in any sequence.

[37] The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often 20 preferred, although any composition stable when exposed to the reaction mixture may be used. For example, stainless steel reactors generally may be used as well.

[38] Typically, equimolar amounts of the tylosin A reagent, piperidinyl compound, and formic acid may be used. Normally, however, excess amounts of the piperidinyl compound and formic acid are used, relative to the molar amount of tylosin A 25 reagent.

[39] In some embodiments, from 1 to about 3 equivalents (or from 1.05 to about 3 equivalents) of the piperidinyl compound are charged to the reactor. In some such embodiments, for example, from 1.05 to about 1.2 equivalents of piperidinyl compound are charged to the reactor. In other such embodiments, from about 1.07 to about 1.5 30 equivalents of piperidinyl compound are charged to the reactor. Here, for example, about 1.3 equivalents of the piperidinyl compound may be charged to the reactor. In some embodiments, the piperidinyl compound is charged to the reactor in two or more separate charges over time, preferably with the subsequent charge(s) being less than the first charge. In some embodiments, for example, the piperidinyl compound is charged to the WO 2008/012343 PCT/EP2007/057710 15 reactor in two charges, with the amount of the second charge being about 10% of the first charge. Applicants have discovered that this can be beneficial for increasing conversion.

[40] In some embodiments, from 1 to about 10 equivalents (or from 1.05 to about 10 equivalents, from about 2 to about 5 equivalents, or from about 2.5 to about 4.5 5 equivalents) of formic acid are used. In some such embodiments, for example, about 4.5 equivalents of formic acid are used. In other such embodiments, from about 2.5 to about 4 equivalents of formic acid are used. For example, in some such embodiments, about 3.0 equivalents of formic acid are used.

[41] Typically, the amount of solvent is sufficient to, for example, prevent (or 10 essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents. In some embodiments, the amount of solvent is at least about 1 L per kg tylosin A reagent (or, where the tylosin A reagent is part of a mixture of tylosin A reagent and derivates thereof, per kg of the total tylosin mixture). The amount of solvent generally is less than 15 about 40 L per kg tylosin A reagent (or tylosin mixture). In some embodiments, the amount of solvent is from about 2 to about 15 L (or from about 5 to about 15 L, from about 5 to about 12 L, from about 5 to about 10 L, or from about 8 to about 10 L) per kg tylosin A reagent (or tylosin mixture). To illustrate, in some such embodiments, the solvent comprises toluene or a mixture of toluene and DCM, and the amount of solvent is 20 from about 8 to about 10 L per kg tylosin A reagent (or tylosin mixture). Here, for example, the amount of solvent may be about 8 L per kg tylosin A reagent (or tylosin mixture).

[42] At least a portion of the reaction (or the entire reaction) is typically conducted at greater than about 20°C, greater than about 25°C, or greater than about 60°C. 25 In general, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and, more typically, is less than the boiling point. When, for example, the solvent is toluene, at least a portion of the reaction (or the entire reaction) is typically conducted at less than about 110°C. Illustrating further, when the solvent is xylene, at least a portion of the reaction (or the 30 entire reaction) is normally conducted at less than about 165°C. In general, at least a portion of the reaction (or the entire reaction) is conducted at from about 60 to about 95°C, from about 70 to about 85°C, from about 70 to about 80°C, or from about 75 to about 80°C. In some embodiments, for example, the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 80°C. In other embodiments, for example, WO 2008/012343 PCT/EP2007/057710 16 the reaction temperature for at least a portion of the reaction (or the entire reaction) is about 76°C. Although lesser temperatures than the above ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than the above ranges may be used, such temperatures tend to coincide with 5 greater production of undesirable byproducts.

[43] This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure. In preferred embodiments, this reaction is conducted under an inert atmosphere 10 (e.g., N2).

[44] The reaction time may depend on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, typically at least about 5 minutes, and more typically at least about 1 hour. The 15 reaction time is generally less than about 24 hours. In some embodiments, for example, the reaction time is from about 0.5 to about 12 hours, or from about 1 to about 4 hours. In some such embodiments, the reaction time is about 3.5 hours. In other such embodiments, the reaction time is from about 1 to about 3 hours. In these embodiments, the reaction time may be, for example, about 2 hours. Although lesser reaction times than these ranges 20 may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.

[45] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step 25 without further purification or isolation. B-2. Preparation of 23-0-Mycinosyl-20-Piperidinyl-5-0-Mycaminosyl-Tylonolide Compound (Hydrolysis of Mycarosyloxy Substituent) 30

[46] In some embodiments, the macrolide synthesis begins by or includes preparing a 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure to Formula (IV): WO 2008/012343 PCT/EP2007/057710 17 oh h3C -(, o, 13 (IV). In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen such that the compound corresponds in structure to: O h3c oh h3c -o o. °' ch3

[47] The 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound may be prepared via acid hydrolysis of a 20-piperidinyl-tylosin compound: WO 2008/012343 PCT/EP2007/057710 18 ch3 20-piperidinyl-tylosin compound ch3 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound When R1, R2, and R3 are each hydrogen, this reaction is as follows: ch3 (acid ch3 5

[48] The 20-piperidinyl-tylosin compound used in the above reaction may be prepared using a process discussed above in Section B-l, prepared using a different process (e.g., a process using a borohydride as a reducing agent), or obtained from a WO 2008/012343 PCT/EP2007/057710 19 commercial vendor. In some preferred embodiments, the 20-piperidinyl-tylosin compound is prepared using a process discussed above in Section B-l.

[49] The acid may, for example, be a strong mineral acid, such as hydrochloric acid (or "HC1"), nitric acid (or "HNO3"), fluoroboric acid (or "HBF4"), sulfuric acid (or 5 "H2SO4"), phosphoric acid (or "H3PO4"), polyphosphonic acid (or "PPA"), or hydrobromic acid (or "HBr"); or a strong organic acid, such as /;-tolucncsulfonic acid or trifluoroacetic acid ("CF3COOH"). In some embodiments, the acid comprises HC1. In other embodiments, the acid comprises HBr. Use of HBr tends to coincide with a less amount of impurities in the product mixture relative to the product obtained using, for 10 example, HC1. In some embodiments, a mixture of acids (particularly a strong acid with another acid) is used.

[50] In general, sufficient acid is mixed with the 20-piperidinyl-tylosin compound to hydrolyze (i.e., cleave) the mycarosyloxy substituent to form a hydroxyl group. Typically, the amount of acid will be at least about one equivalent, based on the 15 amount of 20-piperidinyl-tylosin compound. In general, the acid is added to the reaction mixture in the form of a concentrated composition. The concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30%) (mass/vol), or from about 1 to about 24% (mass/vol). In some embodiments, for example, the acid is HBr, and the concentration of the acid solution added to the 20 reaction mixture is about 24% (mass/vol). In some embodiments, the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.

[51] The ingredients may generally be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, 25 although any composition stable when exposed to the acidic reaction mixture may be used.

[52] At least a portion of the hydrolysis (or the entire hydrolysis) normally is conducted at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous. A temperature of at least about 10°C (or greater than about 15°C, or greater than about 25°C) is typically 30 preferred. In general, the reaction temperature is not greater than the boiling point of the solvent (e.g., water), and typically is less than the boiling point. In some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 100°C (or not greater than about 65°C). In some embodiments where the acid is HC1 or HBr, the reaction temperature over at least a portion of the WO 2008/012343 PCT/EP2007/057710 20 reaction (or the entire reaction) is from about 20 to about 60°C. In some such embodiments, the reaction temperature over at least a portion of the reaction (or the entire reaction) is not greater than about 40°C. In such instances, the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, from about 5 20 to about 40°C, from about 25 to about 40°C, or from about 30 to about 40°C. In other embodiments where the acid is HC1 or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) is from about 45 to about 60°C, or from about 50 to about 56°C. To illustrate, in such embodiments, the reaction temperature over at least a portion of the reaction (or the entire reaction) may be, for example, about 56°C. 10 Although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. And, although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. Such rates, however, may still be suitable, given the ease with which this hydrolysis occurs. 15 [53] The reaction mixture may be maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In such embodiments, the temperature tends to increase once the acid has been charged to the reactor.

[54] This reaction may be conducted over a wide range of pressures, including 20 atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.

[55] The reaction time will depend on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion. 25 In a batch reactor, the reaction time may be less than a minute, essentially spontaneous, or spontaneous. Generally, however, the reaction time is at least about 1 minute, more typically at least about 5 minutes, and still more typically at least about 15 minutes. Normally, the reaction time is less than about 3 hours. In some embodiments, for example, the reaction time is from about 0.25 to about 2 hours, from about 0.25 to about 30 1.5 hours, or from about 0.25 to about 1.1 hours. Although lesser reaction times may be used, such reaction times may coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower. WO 2008/012343 PCT/EP2007/057710 21

[56] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation. B-3. Preparation of 23-Hydroxyl-20-Piperidinyl-5-0-Mycaminosyl-Tylonolide Compound (Hydrolysis of Mycinosyloxy Substituent)

[57] In some embodiments, the macrolide synthesis begins by or includes preparing a 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound, and particularly a compound corresponding in structure for Formula (V): In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or R1 and R3 are each hydrogen, and R2 is methyl. In other embodiments, R1, R2, and R3 are each hydrogen:

[58] The 23 -hydroxyl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound may be prepared via an acid hydrolysis reaction from a 23-0-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound: WO 2008/012343 PCT/EP2007/057710 22 oh 23-0-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonodide compound 23-hydroxy-20-piperidinyl-5-O-mycaminosyl-tylonodide compound Where R1, R2, and R3 are each hydrogen, this reaction is as follows: h3c— ho oh

[59] The 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound used in the above reaction may be prepared using a process discussed above in Section B-2, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound is prepared using a process discussed above in Section B-2.

[60] The acid may, for example, be a strong mineral acid, such as hydrochloric acid, nitric acid, fluoroboric acid, sulfuric acid, phosphoric acid, polyphosphonic acid, or hydrobromic acid; or a strong organic acid, such as /;-tolucncsulfonic acid or trifluoroacetic acid. In some embodiments, the acid comprises HC1. In some preferred embodiments, the acid comprises HBr. As with the hydrolysis discussed above in Section B-2, this preference stems from the tendency of HBr to coincide with a less amount of impurities in the product mixture relative to, for example, HC1. In some embodiments, a mixture of acids (particularly a mixture of a strong acid with another acid) is used.

[61] In embodiments where the mycinosyloxy hydrolysis occurs after the acid hydrolysis of mycarosyloxy discussed above in Section B-2, the acids used in the mycinosyloxy and mycarosyloxy hydrolysis reactions may be different, although it is generally more preferred for the acids to be the same. In some embodiments, for example, HC1 is used in both reactions. In other embodiments, HBr is used in both reactions. WO 2008/012343 PCT/EP2007/057710 23

[62] In general, sufficient acid is mixed with the 23-0-mycinosyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound to hydrolyze the mycinosyloxy substituent to form a hydroxyl group. Typically, the amount of acid will be greater than about one equivalent, based on the molar amount of 23-0-mycinosyl-20-piperidinyl-5-0- 5 mycaminosyl-tylonolide compound. In general, the acid is added to the reaction mixture in the form of a concentrated composition. The concentration typically is not greater than about 50% (mass/vol), not greater than about 48% (mass/vol), from about 1 to about 30% (mass/vol), or from about 1 to about 24% (mass/vol). In some embodiments, for example, the acid is HBr, and concentration of the acid solution added to the reaction mixture is 10 about 24% (mass/vol). In some embodiments, the concentrated acid comprises a mixture of acids, such as, for example, HBr with another acid.

[63] The ingredients may generally be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass and glass-lined reactors are often preferred, 15 although any composition stable when exposed to the acidic reaction mixture may be used.

[64] The mixture normally is maintained at a temperature that is greater than the freezing point of the mixture, allows the mixture to be stirred, and allows for the mixture to be homogenous. The reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is not greater than the boiling point of the solvent (e.g., water), 20 and typically is less than the boiling point. In general, at least a portion of the reaction (or the entire reaction) is conducted at a temperature of at least about 10°C, greater than about 25°C, or at least about 48°C. The reaction temperature over at least a portion of the reaction (or the entire reaction) typically is not greater than about 100°C, or not greater than about 65°C. In some embodiments, for example, the reaction temperature over at 25 least a portion of the reaction (or the entire reaction) is from about 10 to about 100°C. In some embodiments when the acid is HC1 or HBr, the reaction temperature over at least a portion of the reaction (or the entire reaction) preferably is from about 48 to about 60°C. In some such embodiments, for example, the temperature over at least a portion of the reaction (or the entire reaction) is from about 55 to about 60°C. In other such 30 embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 51 to about 57°C (e.g., about 54°C). In still other such embodiments, the temperature over at least a portion of the reaction (or the entire reaction) is from about 50 to about 56°C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater WO 2008/012343 PCT/EP2007/057710 24 temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts.

[65] As with the mycarosyloxy hydrolysis discussed above in Section B-2, the mycinosyloxy hydrolysis reaction mixture may be maintained at a temperature that is 5 slightly less than the desired reaction temperature while at least a portion of the acid (or all the acid) is being charged to the reactor.

[66] This reaction may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric 10 pressure.

[67] The reaction time depends on various factors including, for example, the reaction temperature, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, and more typically at least about 15 minutes. Typically, the reaction time is less than about 7 hours. In some 15 embodiments, for example, the reaction time is from about 0.5 to about 7 hours. In some such embodiments, for example, the reaction time is from about 1 to about 5 hours, or from about 3 to about 5 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production 20 of impurities and inefficient use of equipment and manpower.

[68] When the mycinosyloxy hydrolysis occurs after the mycarosyloxy hydrolysis discussed above in Section B-2, the two reactions (i.e., those described above in Section B-2 and this Section B-3) may be carried out as two discrete steps or as a single reaction. When the reactions are carried out as a single reaction, the reaction mixture may 25 be maintained at the same temperature or changed (typically increased) over time. If the reaction mixture is maintained at the same temperature, the mixture normally is maintained at a temperature of at least about 10°C, typically greater than about 25°C, more typically at least about 30°C, and still more typically at least about 45°C. In some embodiments, the temperature is maintained at from about 10 to about 100°C. In some 30 such embodiments, for example, the temperature is from about 48 to about 70°C. In other such embodiments, for example, the temperature is from about 50 to about 56°C. In other such embodiments, for example, the temperature is from about 55 to about 60°C. In still other such embodiments, the temperature is from about 65 to about 70°C. If the temperature of the mixture is increased over time, the temperature of the mixture at the WO 2008/012343 PCT/EP2007/057710 25 beginning of the hydrolysis normally is at least about 15°C, or at least about 25°C. As the reaction progresses from the mycarosyloxy hydrolysis to the mycinosyloxy hydrolysis, the temperature preferably is increased to at least about 30°C, at least about 45°C, or from about 48 to about 70°C. In some such embodiments, the increased temperature is from 5 about 50 to about 56°C. In other such embodiments, the increased temperature is from about 55 to about 60°C. In still other such embodiments, the increased temperature is from about 65 to about 70°C. In some embodiments, the reaction mixture is maintained at a temperature that is slightly less than the desired reaction temperature while the acid is being charged to the reactor. In those embodiments, the temperature tends to increase 10 once the acid has been charged to the reactor.

[69] The total reaction time when the two hydrolysis reactions are combined depends on various factors including, for example, reaction temperature, relative amounts of the ingredients, and the desired conversion. Generally, however, the reaction time for the combined hydrolysis reactions in a batch reactor is at least about 4 hours. In some 15 embodiments, the combined reaction time is from about 4 to about 6 hours. In some such embodiments, for example, the combined reaction time is about 4 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is from about 65 to about 70°C. In other embodiments, the reaction time is about 5 hours. Such a reaction time may be particularly suitable where, for example, the reaction temperature is 20 from about 55 to about 60°C.

[70] Purification or isolation of the product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation. 25 B-4. Preparation of the Activated Compound

[71] In some embodiments, the macrolide synthesis begins by or includes preparing an activated compound, and particularly a compound that corresponds in structure to Formula (VI): WO 2008/012343 PCT/EP2007/057710 26 i ^OH oh ch3 (VI).

[72] In some embodiments, R1 and R3 are each methyl, and R2 is hydrogen; or

[73] L is a leaving group. In general, the leaving group is a group that may be replaced with a piperidinyl group (normally via nucleophilic displacement) using piperidine in an amination reaction, such as the amination reaction discussed below in Section B-5. In some embodiments, for example, L is iodo (-1), bromo (-Br), alkylsulfonate, and arylsulfonate. The alkylsulfonate and arylsulfonate are optionally substituted with one or more substituents independently selected from the group consisting of halo, alkyl, and haloalkyl. In some such embodiments, for example, L is iodo, bromo, methylsulfonate (or "-0S(0)2CH3" or "mesylate"), trifluoromethylsulfonate (or "-0S(0)2CF3" or "triflate"), or 4-methylphenylsulfonate (or "/?-toluenesulfonate" or "tosylate"). In some embodiments, L is iodo, and the activated compound corresponds in structure to: 13 2 12 3 R and R are each hydrogen, and R is methyl. In other embodiments, R , R , and R are each hydrogen, such that the compound corresponds in structure to: ch3 WO 2008/012343 PCT/EP2007/057710 or, when R1, R2, and R3 are each hydrogen, corresponds in structure to: ch3 In some embodiments, L is mesylate, and the activated compound corresponds in structure 5 to: or, when R1, R2, and R3 each are hydrogen, corresponds in structure to: In some embodiments, L is tosylate, and the activated compound corresponds in structure 10 to: WO 2008/012343 PCT/EP2007/057710 28 ch3 or, when R1, R2, and R3 each are hydrogen, corresponds in structure to: ch3 In some embodiments, L is triflate, and the activated compound corresponds in structure 5 to: ch3 or, when R1, R2, and R3 each are hydrogen, corresponds in structure to: ch3 10

[74] The activated compound may be prepared via an activation reaction from a 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound and an activating agent {i.e., a compound comprising an electron withdrawing group): WO 2008/012343 PCT/EP2007/057710 29 ho oh + ACTIVATING AGENT i r1 oh CH. CH. 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound activated compound Where R1, R2, and R3 are each hydrogen, this reaction is as follows: ho oh + ACTIVATING AGENT ch- oh

[75] The 23 -hydroxyl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound used in the above reaction may be prepared using a process discussed above in Section B-3, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound is prepared using a process discussed above in Section B-3.

[76] In some embodiments, L is iodo, and the activating agent is formed by mixing h and triphenylphosphine:

[77] Typically, this reaction is conducted in the presence of one or more solvents. In general, the solvent is non-reactive with the reagents, products, and any other ingredients in the reaction mixture (although, as noted below, the solvent may, for example, act as a helping base). The solvent may be, for example, one or more of dichloromethane ("DCM"), acetone, acetonitrile ("ACN"), tert-butyl methyl ether (or "tBME"), toluene, and pyridine. In some embodiments, for example, the solvent WO 2008/012343 PCT/EP2007/057710 30 comprises tetrahydrofuran ("THF"). In other embodiments, the solvent comprises pyridine, which also may act as a helping base. In still other embodiments, the solvent comprises dichloromethane. In some such embodiments, for example, the solvent comprises both dichloromethane and toluene. In some embodiments, the ratio of 5 dichloromethane to toluene is, for example, be at least about 1:1, from about 3:1 to about 10:1, or from about 3:1 to about 5:1. In some embodiments, at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound.

[78] In general, the amount of solvent is sufficient to, for example, prevent (or 10 essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, dissolve the reagents (particularly the 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound), and promote homogenous distribution of the reagents. The amount of solvent typically is at least about 1 L per kilogram of the 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound. 15 The amount of solvent typically is not greater than about 100 L per kilogram of the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. In some embodiments, the amount of solvent is from about 5 to about 20 L (or from about 5 to about 15 L, or from about 10 to about 12 L) per kilogram of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. To illustrate, in some embodiments, the amount of 20 solvent is about 10 L DCM per kilogram. In other embodiments, the amount of solvent is about 12 L DCM per kilogram. In still other embodiments, the solvent is a mixture of DCM and toluene (about 4:1 vol/vol), and the amount of solvent is about 10 L per kilogram.

[79] As indicated above, this reaction may be conducted in the presence of a 25 base (or "helping base"). The base may be a single base, or a combination of bases. This base may comprise, for example, triethylamine, pyridine, imidazole, potassium carbonate, and/or 4-dimethylaminopyridine (or "DMAP"). The presence of the base may increase the reaction rate. In some embodiments, the base comprises pyridine. In some such embodiments, for example, the activating agent comprises h and triphenylphosphine. In 30 other embodiments, the base comprises imidazole. In other embodiments, the base comprises a combination of potassium carbonate and 4-dimethylaminopyridine. In some such embodiments, for example, the activating agent comprises /;-tolucncsulfonyl chloride. In some embodiments, the helping base is attached to a solid support (e.g., a resin). WO 2008/012343 PCT/EP2007/057710 31

[80] When a base is used, the molar amount of the base is typically at least equivalent to the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound. In some embodiments, the amount of the base is at least 1.05 equivalents. For example, in some embodiments, the molar amount of the base is from 5 about 1.1 to about 10 equivalents, from about 1.1 to about 5 equivalents, or from about 1.1 to about 3 equivalents. In some such embodiments, the molar amount of base is from about 1.1 to about 1.4 equivalents (e.g., about 1.15 or about 1.3 equivalents). In other such embodiments, the molar amount of the base is about 2.8 equivalents. When a combination of bases is used, the total molar amount of base preferably falls within the 10 ranges described above. For example, when the source of the activating agent comprises /;-tolucncsulfonyl chloride, an example of a contemplated amount of base is about 1.5 equivalents of potassium carbonate and about 1.0 equivalents of 4-dimethylaminopyridine, based on the amount of the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. 15 [81] When the source of the activating agent is h and triphenylphosphine, the h, triphenylphosphine, and base (if present) are typically first combined in the presence of solvent to form the activating agent before they are combined with the 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound. The reactor in which the activating agent is formed may be the same reactor in which the activating agent is combined with 20 the 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound. Alternatively, the activating agent may be formed in a different reactor, and then charged to the reactor to which the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound is charged. The h may be added in one or more doses to the triphenylphosphine or vice versa. In some embodiments, the h is added to the triphenylphosphine in two or more 25 portions (e.g., 5 portions) or vice versa. The portions may be equal or different amounts. Generally, the combination of the h and triphenylphosphine takes place in the presence of a solvent, which may, for example, comprise the solvent(s) that is used in the substitution reaction. If a base (e.g., pyridine) is present, it is typically combined with the triphenylphosphine before the h is added. The mixture preferably is maintained at from 30 about 15 to about 35°C (or from about 20 to about 30°C, e.g., about 25°C) during the addition of h to the triphenylphosphine, and then maintained at a temperature of from about 15 to about 35°C (or from about 20 to about 30°C, e.g., about 25°C) after the addition for at least about one minute (e.g., about 2 minutes), or for at least about 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., WO 2008/012343 PCT/EP2007/057710 32 about 40 minutes). Afterward, the temperature preferably is adjusted to a temperature that is approximately equal to the temperature at which the substitution reaction is to be initiated.

[82] To perform the substitution reaction, equimolar amounts of the 23- 5 hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound and activating agent generally may be used. Normally, however, an excess of the activating agent is used, and typically at least 1.05 equivalents are used, based on the molar amount of 23-hydroxyl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound.

[83] In some embodiments when the activating agent is formed from h and 10 triphenylphosphine, the molar amounts of h and triphenylphosphine are each at least 1.05 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. For example, in some such embodiments, the molar amounts of h and triphenylphosphine are each from 1.05 to about 10 equivalents, from 1.05 to about 5 equivalents, or from 1.05 to about 3 equivalents. Although the equivalents of each of h 15 and triphenylphosphine may be the same, the equivalents of triphenylphosphine typically exceeds the equivalents of h. To illustrate, suitable molar amounts of h and triphenylphosphine may be about 2.5 and 2.6 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. In other embodiments, suitable molar amounts of h and triphenylphosphine are about 1.9 and 2.0 20 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. In still other embodiments, a suitable molar amount of h is from 1.05 to about 1.2 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound; and a suitable amount of triphenylphosphine is from about 1.09 to about 1.25 equivalents, based on the molar 25 amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. For example, suitable molar amounts of h and triphenylphosphine may be about 1.06 and about 1.13 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound. Exemplifying further, suitable molar amounts of h and triphenylphosphine may alternatively be about 1.2 and about 1.25 30 equivalents, respectively, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound.

[84] In some embodiments when the activating agent is /;-tolucncsulfonyl chloride, the molar amount of/;-tolucncsulfonyl chloride is from about 1.1 to about 10 equivalents, from about 1.2 to about 5 equivalents, or from about 1.2 to about 3 WO 2008/012343 PCT/EP2007/057710 33 equivalents, based on the molar amount of 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound. A suitable molar amount of /^-toluenesulfonyl chloride may be, for example, 1.2 equivalents.

[85] The substitution reaction may be conducted over a wide range of pressures, 5 including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.

[86] The reaction temperature for at least a portion of the substitution reaction (or the entire substitution reaction) typically is greater than the freezing point of the 10 solvent. In general, the reaction temperature over at least a portion of the substitution (or the entire substitution) is not greater than the boiling point of the solvent, and typically is less than the boiling point. In some embodiments, for example, the solvent is dichloromethane, and at least a portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 45°C. In some embodiments, at least a 15 portion of the reaction (or the entire reaction) is conducted at a temperature that is not greater than about 32°C, or not greater than about 25°C. In some such embodiments, for example, at least a portion of the reaction (or the entire reaction) is conducted at from about -10°C to about 25°C. For example, in some embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about zero to about 20°C, or from 20 about 12 to about 18°C (e.g., about 13°C). In other embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about -10°C to about 45°C, or from about 25 to about 45°C. In still other embodiments, at least a portion of the reaction (or the entire reaction) is conducted at from about -10 to about 0°C, or from about -6 to about -5°C. Although lesser temperatures than these ranges may be used, such temperatures tend 25 to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. Use of some sources of the activating agent (e.g., toluenesulfonyl chloride), however, may allow for greater temperatures to be used (e.g., from about 25 to about 45°C). When the activating agent is iodine, it is typically preferred to conduct the 30 substitution reaction within a temperature range that does not produce an unacceptable level of impurities resulting from di-iodination of the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound.

[87] The reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, WO 2008/012343 PCT/EP2007/057710 34 and the desired conversion. In a batch reactor, the total reaction time is typically at least about 1 minute, and more typically at least about 45 minutes. In general, the total reaction time is less than about 24 hours. In some embodiments, for example, the total reaction time is less than about 5 hours. To illustrate, in some embodiments, the reaction time is 5 from about 45 minutes to about 5 hours, or from about 1 to about 3 hours. In some such embodiments, for example, the reaction time is from about 2 to about 3 hours, or from about 2 to about 2.5 hours (e.g., about 2 or about 2.2 hours). In other embodiments, the reaction time is from about 5 to about 10 hours, from about 6 to about 10 hours, from about 7 to about 10 hours, or from about 7 to about 8 hours. Although lesser reaction 10 times than these ranges may be used, such reaction times tend to coincide with lesser conversions. And, although greater reaction times may be used, such reaction times tend to coincide with greater production of impurities and inefficient use of equipment and manpower.

[88] Due to the exothermic nature of the substitution reaction, in some 15 embodiments (particularly those using a batch reactor), the 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound is combined with the activating agent over time (or in multiple separate doses) rather than all at once. In some embodiments, this occurs over a period of at least one minute, at least 5 minutes, from about 5 to about 60 minutes, or from about 30 to about 60 minutes (e.g., about 50 minutes). To illustrate, in some 20 embodiments, the substitution reaction is conducted at a maximum temperature of about 25°C, and the dosing of the activating agent occurs over from about 0.5 to about 1 hour, followed by an additional reaction time of about 1 hour. In other embodiments, the substitution reaction is conducted at a maximum temperature of about -5°C, and the dosing of the activating agent occurs over from about 0.7 to about 1 hour, followed by an 25 additional reaction time of about 7 hours.

[89] In some embodiments, the substitution reaction is quenched to inactivate any residual iodine, and, therefore, reduce (and preferably prevent) by-product formation due to such residual iodine. For example, in some such embodiments, the reaction is quenched with aqueous sodium sulfite (i.e., Na2S03). Purification or isolation of the 30 product may be achieved using, for example, various methods known in the art. Alternatively, the product may be used in the next step without further purification or isolation.

[90] Both the activating agent formation reaction and the substitution reaction may be conducted in various reactor types. In some embodiments, for example, the WO 2008/012343 PCT/EP2007/057710 35 reactor is a stirred-tank reactor. The reactor may be made of any composition that remains stable when exposed to the reaction mixture. Such materials include, for example, various materials, such as glass (including glass-lining) or stainless steel. B-5. Preparation of the Macrolide [91] As noted above, the macrolides prepared in accordance with this invention correspond in structure to Formula (I): Here: As to R1, R2, and R3: R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R\R2, andR3 are each hydrogen. As to R4, R5, and R6: R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. In some embodiments, R1, R2, R3, R4, R5, and R6 are each hydrogen: (I-A). WO 2008/012343 PCT/EP2007/057710 36 In some such embodiments, for example, the compound corresponds in structure to the following formula: (I-B).

[92] In some embodiments, the preparation of the macrolide begins by or includes an amination reaction of an activated compound with a piperidinyl compound: PH hox n"ltl3 oh + ch, activated compound n h piperidinyl reagent R r3 H3C\ pH hox n"l±13 oh macrolide Where R1, R2, R3, R4, R5, and R6 are each hydrogen, this reaction is as follows: N H CH, CH,

[93] The activated compound used in the above reaction may be prepared using a process discussed above in Section B-4, prepared using a different process, or obtained from a commercial vendor. In some preferred embodiments, the activated compound is prepared using a process discussed above in Section B-4.

[94] Typically, this reaction is conducted in the presence of one or more solvents. In general, the solvent is non-reactive with the reagents (e.g., the activated compound), products, and any other ingredients in the reaction mixture. The solvent may be, for example, acetonitrile (or "CH3CN"); chloroform; dichloromethane; WO 2008/012343 PCT/EP2007/057710 37 tetrahydrofuran; a ketone solvent, such as acetone (or "CH3COCH3"); a hydrocarbon solvent, such as an aromatic hydrocarbon solvent (e.g., toluene or xylene); or a base, such as pyridine or piperidine. In some embodiments, the solvent comprises acetonitrile. In some embodiments, the solvent comprises tetrahydrofuran. In some embodiments, the 5 solvent comprises dichloromethane. In some embodiments, the solvent comprises xylene. In some embodiments, at least a portion of the solvent comprises solvent from a process step used during the preparation and/or purification of the activated compound.

[95] The amount of solvent can vary widely, from no solvent at all to amounts that create diluted reaction mixtures. Typically, the amount of solvent is sufficient to, for 10 example, prevent (or essentially prevent) the reagents, products, and other ingredients in the reaction mixture from sticking to the reactor, and promote homogenous distribution of the reagents. In some embodiments, sufficient solvent is present such that the combined amount of activating reagent and macrolide is from about 5 to about 50% (mass/volume) of the reaction mixture. In some embodiments, the amount of solvent is at least about 1 L 15 per kilogram activated compound. In some such embodiments, for example, the amount of solvent is from about 1 to about 100 L (or from about 1 to about 20 L) per kilogram of activated compound. To illustrate, in some embodiments, about 5 L of solvent (e.g., xylene or tetrahydrofuran) are used per kilogram of activated compound. Illustrating further, in other embodiments, about 10 L of solvent (e.g., acetonitrile) are used per 20 kilogram of activated compound.

[96] In some embodiments, the amination is conducted in the presence of a base. In some embodiments, the base comprises an un-hydrated base. The base may be, for example, potassium carbonate (or "K2CO3"), sodium carbonate (or "Na2C03"), or a tertiary amine. The presence of such a base tends to coincide with a greater reaction rate 25 and less production of impurities. It is believed that such advantages may stem from the base deprotonating protonated piperidinyl compound. The base preferably is not so strong as to cause hydrolysis of the lactone in the macrolide core. Generally, equimolar amounts of the activated compound and base may be used. Normally, however, an excess of base is used. In some embodiments, at least 1.05 (or from about 1.1 to about 50, from about 2 30 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of base are used, based on the molar amount of activated compound charged to the reactor. In some such embodiments, about 6.2 equivalents of base are used. In other some such embodiments, about 10 equivalents of base are used. In still other such embodiments, from about 1.1 to about 10 (or from about 2 to about 8, or from about 4 to about 6) WO 2008/012343 PCT/EP2007/057710 38 equivalents of base are used, based on the molar amount of activated compound charged to the reactor. To illustrate, a suitable amount of base may be, for example, about 5 equivalents.

[97] To perform the amination, the activated compound, piperidinyl compound, 5 and solvent, as well as any base (to the extent present), are normally charged to a reactor and mixed. These ingredients generally may be charged to the reactor in any sequence. The reactor may comprise various reactor types. In some embodiments, for example, the reactor is a stirred-tank reactor. Glass, glass-lined, and stainless steel reactors are often preferred, although any composition stable when exposed to the reaction mixture may be 10 used.

[98] Generally, equimolar amounts of the activated compound and piperidinyl compound may be used. Normally, however, an excess of the piperidinyl compound is used. In some embodiments, at least 1.05 (or from about 1.1 to about 50, from about 2 to about 30, from about 2 to about 20, or from about 2 to about 10) equivalents of the 15 piperidinyl compound are used, based on the molar amount of activated compound charged to the reactor. In some such embodiments, about 10 equivalents of the piperidinyl compound are used. In other such embodiments, from about 2 to about 8 (or from about 4 to about 6) equivalents are used, based on the molar amount of activated compound charged to the reactor. To illustrate, a suitable amount of piperidinyl compound may be, 20 for example, about 4.7 equivalents. A contemplated suitable amount of piperidinyl compound also may be, for example, about 5.7-5.8 equivalents.

[99] At least a portion of the reaction (or the entire reaction) normally is conducted at greater than about 20°C, or greater than about 25°C. The optimal reaction temperature depends on, for example, the solvent. Typically, at least a portion of the 25 reaction (or the entire reaction) is conducted at a temperature that is not greater than the boiling point of the solvent, and typically is less than the boiling point. In general, at least a portion of the reaction (or the entire reaction) is conducted at from about 50 to about 110°C. In some embodiments, for example, at least a portion of the reaction (or the entire reaction) is conducted at from about 60 to about 110°C, or from about 75 to about 110°C. 30 To illustrate, when the solvent comprises acetonitrile or toluene, a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 78°C to about 110°C (e.g., about 78°C). To illustrate further, when the solvent comprises xylene, a suitable contemplated reaction temperature for at least a portion of the reaction (or the entire reaction) is from about 95 to about 105°C, and a suitable reaction WO 2008/012343 PCT/EP2007/057710 39 time for the reaction is about 15 hours. In other embodiments, the solvent comprises tetrahydrofuran, and at least a portion of the reaction (or the entire reaction) is conducted at from about 55 to about 75°C. Although lesser temperatures than these ranges may be used, such temperatures tend to coincide with slower reaction rates. And, although greater temperatures than these ranges may be used, such temperatures tend to coincide with greater production of undesirable byproducts. Typically, lesser temperatures may be used with solvents having greater polarities. The temperature can be adapted accordingly by one skilled in the art.

[100] In some embodiments, the amination reaction is conducted at more than one temperature. For example, the reaction may be conducted at one temperature initially, and then slowly increased to another temperature as the reaction progresses.

[101] The amination may be conducted over a wide range of pressures, including atmospheric pressure, less than atmospheric pressure, and greater than atmospheric pressure. It is typically preferred, however, to conduct the reaction at about atmospheric pressure.

[102] The reaction time depends on various factors including, for example, the reaction temperature, characteristics of the solvent, relative amounts of the ingredients, and the desired conversion. In a batch reactor, the reaction time is generally at least about 1 minute, at least about 5 minutes, or at least about 45 minutes. The reaction time is generally no greater than about 24 hours. In some embodiments, the reaction time is from about 2 to about 15 hours. In other embodiments, the reaction time is from about 1 to about 5 hours, from about 2 to about 4 hours, or from about 2 to about 3 hours (e.g., about 2.5 hours). In other such embodiments, the reaction time is from about 6 to about 15 hours. Although lesser reaction times than these ranges may be used, such reaction times tend to coincide with lesser conversions.

[103] Further purification or isolation of the product may be achieved using, for example, various methods known in the art. WO 2008/012343 PCT/EP2007/057710 40 B-6. Examples of Contemplated Reaction Schemes [104] This invention contemplates any processes that use any of the above reactions. In some embodiments, the process will comprise one of the above reactions. In other embodiments, the process will comprise two, three, four, or all the above reactions. The following Scheme I generically illustrates a scenario where all the above reactions are used: Scheme I Here: As to R1, R2, and R3: R1 and R3 are each methyl, and R2 is hydrogen; R1 and R3 are each hydrogen, and R2 is methyl; or R\R2, andR3 are each hydrogen. As to R4, R5, and R6: R4 and R6 are each methyl, and R5 is hydrogen; R4 and R6 are each hydrogen, and R5 is methyl; or R4, R5, and R6 are each hydrogen. L is a leaving group. WO 2008/012343 PCT/EP2007/057710 41

[105] The following Scheme II generically illustrates the above scenario where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the source of the activating agent comprises h, triphenylphosphine, and pyridine; and the final amination reaction mixture comprises 5 potassium carbonate: WO 2008/012343 PCT/EP2007/057710 42

[106] The following Scheme III generically illustrates the scenario of Scheme I where the two hydrolysis reactions are conducted without stopping the first hydrolysis or isolating product from the first hydrolysis before conducting the second hydrolysis: WO 2008/012343 PCT/EP2007/057710 43

[107] The following Scheme IV generically illustrates the scenario of Scheme I where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the first hydrolysis is not stopped and the product of the first hydrolysis is not isolated before conducting the second hydrolysis; the source of 5 the activating agent comprises h, triphenylphosphine, and pyridine; and the final amination reaction mixture comprises potassium carbonate: Scheme IV WO 2008/012343 PCT/EP2007/057710 44

[108] The following Scheme V generically illustrates a 2-stage scenario of Scheme I where the non-polar solvent in the reductive amination comprises toluene; the acids in the hydrolysis reactions comprise HBr; the reductive amination and first hydrolysis are not stopped and the products of the reductive amination and first hydrolysis are not isolated before conducting the second hydrolysis; the source of the activating agent comprises h, triphenylphosphine, and pyridine; the final amination reaction mixture comprises potassium carbonate; and the activation reaction is not stopped and the product of the activation reaction is not isolated before conducting the final amination reaction: Scheme V B-7. Tylosin Reagent [109] In general, the tylosin reagent used in the processes of this invention comprises tylosin A (or a salt thereof): Tylosin A. WO 2008/012343 PCT/EP2007/057710 45 Although this invention contemplates the use of pure (or at least essentially pure) tylosin A (or a salt thereof), various commercially available tylosin compositions additionally or tylosin B (also known as desmycocin), tylosin C (also known as macrocin), and tylosin D (also known as relomycin). In general, these derivatives, if present, are present in only small amounts. In some embodiments, the weight ratio of tylosin A to the total combined amount of tylosin A derivatives in the composition is at least about 1:1. In some such embodiments, for example, the ratio is at least about 4:1, at least about 10:1, at least about 95:5, at least about 98:2, or at least about 99:1. In other such embodiments, about 100% (by weight) of the tylosin compounds (i.e., tylosin A and tylosin A derivatives) in the composition consists of tylosin A. Other embodiments are contemplated wherein the tylosin A makes WO 2008/012343 PCT/EP2007/057710 46 up less than 50% (by weight) of the tylosin compounds in the composition. To illustrate, in some such embodiments, the weight ratio of tylosin D to the total combined amounts of tylosin A and other tylosin A derivatives is at least about 1:1, at least about 4:1, at least about 9:1, at least about 95:5, at least about 98:2, or at least about 99:1. In other such 5 embodiments, about 100% (by weight) of the tylosin compounds in the composition consists of tylosin D.

[110] The methods discussed above for making 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide from tylosin A generally can be used (and, to the extent desirable, modified) for making 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide from tylosin B, C, 10 and/or D in addition to (or instead of) tylosin A.

[111] Tylosin B, for example, has a hydroxyl instead of a mycarosyl substituent on the 5-mycanimosyl. Thus, a 20-piperidinyl intermediate derived from tylosin B does not require the first hydrolysis reaction discussed above in Section B-2. To the extent such an intermediate is exposed to the hydrolysis method discussed in Section B-2, the 15 intermediate will generally remain non-reactive or begin hydrolyzing at the 23-mycinosyloxy substituent.

[112] Tylosin C has a hydroxyl rather than a methoxy at the 3-position of the 23-mycinosyloxy substituent. This difference generally has no effect with respect to the above-described methods. The sugar normally will cleave (i.e., hydrolyze) in the same 20 manner and under the same conditions as the 23-mycinosyloxy of tylosin A during the hydrolysis described above in Section B-3.

[113] Tylosin D has a hydroxyl rather than a carbonyl at the 20-position. This hydroxyl is generally not transformed into a piperidinyl using the reductive amination method described above in Section B-l. Depending on the reaction conditions, however, 25 it may become activated during the activation reaction described above in Section B-4, and then aminated with piperidine along with the 23-position during the amination method described above in Section B-5. C. Salts of Intermediates and Macrolides 30 [114] This invention may be used to prepare macrolide compounds or intermediates both in the form of free compounds and in the form of salts. In addition, the reagents used in this invention may be in the form of salts. Salts may be, for example, acid addition salts. In general, an acid addition salt can be prepared using any inorganic or organic acid. Depending on the particular compound (and/or its crystalline structure), a WO 2008/012343 PCT/EP2007/057710 47 salt of a compound may be advantageous due to one or more of the salt's chemical or physical properties, such as stability in differing temperatures and humidities, or a desirable solubility in water, oil, or other solvent. In some instances, a salt of a compound also may be used as an aid in the isolation or purification of a compound. In some 5 embodiments (particularly where the salt is intended to be administered to an animal, as opposed to, for example, being used in an in vitro context), the salt is pharmaceutically acceptable.

[115] Salts can typically be formed by, for example, mixing the free macrolide or intermediate compound with an acid using various known methods in the art. Examples of 10 often suitable inorganic acids include hydrochloric, hydrobromic, hydro iodic, nitric, carbonic, sulfuric, and phosphoric acid. Examples of often suitable organic acids include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids. Specific examples of often suitable organic salts include cholate, sorbate, laurate, acetate, trifluoroacetate (or "CF3COOH" or "TFA"), formate, 15 propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartrate (and derivatives thereof, such as dibenzoyltartrate), citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, mesylate, stearate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate (and derivatives thereof), embonate (pamoate), ethanesulfonate, benzenesulfonate, pantothenate, 2-20 hydroxyethanesulfonate, sulfanilate, cyclohexylaminosulfonate, P-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycerophosphate, heptanoate, hexanoate, nicotinate, 2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, tosylate, and undecanoate. In some 25 embodiments, the salt comprises a hydrochlorate, trifluoroacetate, mesylate, tosylate, tartrate, or citrate salt. D . Preparation of Medicaments and Methods of Treatment Using Macrolides

[116] The macrolides prepared by the above-described processes may generally 30 be used, for example, to treat pasteurellosis in animals, particularly livestock and poultry. In some embodiments, such a macrolide(s) is used to treat bovine animals having bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni. In other embodiments, such a macro lide(s) is used to WO 2008/012343 PCT/EP2007/057710 48 treat swine animals having swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, and Bordetella bronchiseptica.

[117] In general, a therapeutically-effective amount of one or more of such macrolides is administered to the recipient animal. As used in this patent, the term 5 "therapeutically effective amount" constitutes an amount that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection. Generally, the therapeutically effective amount is defined as the amount necessary to achieve a concentration efficacious to control the target pathogen(s) at the site of infection (or, when used to prevent, reduce the risk of, or delay the onset of 10 infection, at a site susceptible to infection). The concentration at the site of infection (or at a site susceptible to infection) is preferably at least equal to the MIC90 level (minimum inhibitory concentration, i.e., the concentration that inhibits the growth of 90% of the target pathogen) of the macrolide for the target pathogen. Such an amount may be administered to the animal recipient in two or more separate doses, although preferably is 15 administered in a single dose. To the extent the macrolide(s) is administered with another active ingredient(s), the term "therapeutically effective amount" refers to the total amount of the macro lide(s) combined with the other active ingredient(s) that is sufficient to prevent, reduce the risk of, delay the onset of, ameliorate, suppress, or eradicate a target pathogen(s) infection. 20 [118] Factors affecting the preferred dosage regimen include the type (e.g., species and breed), age, weight, sex, diet, activity, and condition of the animal recipient; the severity of the pathological condition; the apparatus used to administer the composition, as well as the type of administration used; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular 25 composition administered; the existence of an additional active ingredient(s) in the composition; and whether the composition is being administered as part of a drug and/or vaccine combination. Thus, the dosage actually employed can vary for specific animal patients, and, therefore, can deviate from the typical dosages set forth above. Determining such dosage adjustments is generally within the skill of those in the art using conventional 30 means.

[119] In general, the macro lide(s) may be administered once to an animal, although it is contemplated that it may instead be administered multiple times.

[120] For cattle, the total amount of administered macrolide(s) is typically from about 0.1 to about 40 mg per kg body weight, and more typically from about 1 to about 10 WO 2008/012343 PCT/EP2007/057710 49 mg per kg body weight. For example, in some embodiments, the amount administered to cattle is about 4 mg per kg body weight. Although the macro lide(s) may be given to cattle at any age, in some embodiments, the macro lide(s) is administered to cattle that are from about 1 months to about 1.5 years old, or from about 6 months to about 1 year old. In 5 some embodiments, the macro lide(s) is administered to weaned calves entering the feedlots (often at about 6 months old). In still other embodiments, the cattle are calves at from about 2 to about 12 weeks old, and the macrolide(s) is administered for prophylaxis at a dosage of from about 1 to about 10 mg per kg of the body weight; or for treating an existing infection at a dosage of from about 2 to about 20 mg per kg of the body weight. 10 [121] For swine, the total amount of administered macrolide(s) is typically from about 0.1 to about 50 mg per kg body weight, and more typically from about 1 to about 10 mg per kg body weight. For example, in some embodiments, the amount administered to swine is about 4 mg per kg body weight. In other embodiments, the amount administered to swine is about 5 mg per kg body weight. Although the macro lide(s) may be given to 15 swine at any age, in some embodiments, the macrolide(s) is administered to grower-finisher pigs.

[122] The method of administration can be varied depending on animals, but in the case of large mammals such as cattle, swine, and horses, it is preferably administered orally or parenterally. "Parenteral administration" includes, for example, subcutaneous 20 injections, intravenous injections, intramuscular injections, intrasternal injections, submucosal injections, and infusion. In some embodiments, for example, the animal recipient is a bovine animal, and the macrolide composition is administered subcutaneously, such as in the neck. In other embodiments, for example, the animal recipient is a swine animal, and the macrolide composition is administered 25 intramuscularly.

[123] The macro lide(s) may be used to form a pharmaceutical composition (or "medicament"). It is contemplated that such a composition may entirely comprise one or more macrolides. Normally, however, the composition comprises other ingredients as well. 30 [124] Other ingredients in the composition may comprise, for example, other active ingredients. Alternatively (or in addition), such other ingredients may comprise one or more pharmaceutically acceptable carriers, vehicles, and/or adjuvants (collectively referred to as "excipients"). The selection of such excipients will depend on various factors, such as the mode of administration; the apparatus used to administer the WO 2008/012343 PCT/EP2007/057710 50 composition; pharmacological considerations, such as the activity, efficacy, pharmacokinetic, and toxicology profiles of the particular composition; the existence of an additional active ingredient(s) in the composition; and whether the composition is being administered as part of a drug and/or vaccine combination. 5 [125] Solid macrolide compositions may comprise, for example, saccharides such as lactose, glucose, and sucrose; starches, such as corn starch and potato starch; cellulose derivatives, such as carboxymethylcellulose sodium, ethylcellulose, and cellulose acetate; etc.

[126] Liquid macrolide compositions may comprise for example, water, isotonic 10 physiological saline, Ringer's solution, ethyl alcohol, and/or phosphate buffer solution may be present. Such compositions also may comprise oils, such as peanut oil, cotton seed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil and/or polyhydric alcohols such as glycerol, propylene glycol, sorbitol, mannitol, polyethylene glycol, and poly(ethylene glycol-2-propylene glycol-2-polyethylene glycol). It also, for example, may 15 be desirable in some instances for the composition to comprise one or more preservatives. The presence of a preservative may, for example, provide a benefit for compositions or solvents that may be stored over lengthy periods of time, e.g., days, weeks, months, or years. When selecting a suitable preservative, factors to consider include, for example, its antimicrobial activity; the pH range at which it has the desired antimicrobial activity; the 20 minimum concentration at which it has the desired antimicrobial activity; its aqueous solubility and other physical characteristics (e.g., potential to cause foaming); its suitability for parenteral use; its possible interactions with the active ingredient(s) (e.g., its effect on the solubility of an active ingredient); its possible interactions with the non-active ingredients (e.g., its effect on the stability of the solvent); and any government 25 regulations that may be applicable where the composition or solvent is being manufactured, sold, or used. Contemplated preservatives include, for example, parabens, propylene glycol, benzalkonium chloride, phenylethanol, chlorocresol, metacresol, ethanol, phenoxyethanol, and benzyl alcohol.

[127] Further discussion regarding pharmaceutically acceptable excipients that 30 may be suitable for the macrolide composition may be found in, for example, "Gennaro, Remington: The Science and Practice of Pharmacy" (20th Edition, 2000) (incorporated by reference into this patent). To illustrate, other suitable excipients may include, for example, coloring agents; flavoring agents; and thickening agents, such as povidone carboxymethylcellulose, and/or hydroxypropyl methylcellulose. WO 2008/012343 PCT/EP2007/057710 51

[128] Normally, the macro lide(s) occupies at least about 0.5% by weight of the pharmaceutical composition. For example, in some embodiments for swine use, suitable macrolide concentrations for parenteral administration may be, for example, from about 5 to about 500 mg/ml, from about 10 to about 100 mg/ml, or from about 20 to about 60 5 mg/ml (e.g., about 40 mg/ml). Exemplifying further, in some embodiments for bovine use, suitable macrolide concentrations for parenteral administration may be, for example, from about 5 mg/ml to about 2.0 g/ml, from about 10 mg/ml to about 1.0 g/ml, 50 to about 500 mg/ml, or from about 100 to about 300 mg/ml (e.g., 180 mg/ml).

[129] It should be recognized that the macrolide concentration can be varied 10 depending on the dosage form. Where, for example, the macrolide(s) is administered parenterally, the macrolide concentration preferably is sufficient to provide the desired therapeutically effective amount of the macrolide(s) in a volume that is acceptable for parenteral administration. The maximum acceptable volume may vary, depending on, for example, the apparatus being used for the administration, type of parenteral 15 administration, size of the recipient animal, and subjective desires of the user.

[130] Further discussion relating to the use of 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide and derivatives thereof to treat livestock and poultry disease may be found in, for example, U.S. Patent No. 6,514,946. As indicated earlier, that discussion is incorporated by reference into this patent. 20 [131] This invention also is directed to kits that are, for example, suitable for use in performing the methods of treatment described above. The kit comprises a therapeutically effective amount of at least one of the above-described macrolides, and instructions for combining the macrolide(s) with at least one excipient, such as, for example, instructions for dissolving or suspending the macrolide(s) in a liquid excipient. 25 The kit may further (or alternatively) comprise additional components, such as, for example, one or more apparatuses (e.g., a syringe) for administering a composition comprising (or derived from) the macrolide(s), one or more additional pharmaceutical or biological materials, one or more excipients, and/or one or more diagnostic tools. WO 2008/012343 PCT/EP2007/057710 52 EXAMPLES

[132] The following examples are merely illustrative of embodiments of the invention, and not limiting to the remainder of this disclosure in any way. 5 [133] Example 1. Preparation of 20,23-dipiperidinyl-5-0-mycaminosyl- tylonolide from tylosin A.

[134] Part A. Reductive amination. Preparation of 23-0-Mycinosyl-20-10 Piperidinyl-5-O-Mycaminosyl-Tylonolide Compound (2). (1) (2) Toluene (19.2 kg), tylosin A (1) (3.68 kg; >80% tylosin A; >95% tylosin A, B, C, & D), piperidine (0.40 kg), and formic acid (0.55 kg) were charged to a reactor. The mixture was heated to 70-80°C, while being stirred. Stirring was then continued at that 15 temperature for 1-2 more hours. The formation of the 20-piperidinyl-tylosin compound WO 2008/012343 PCT/EP2007/057710 53 (2) was monitored by HPLC. After reaction completion (< 2% tylosin A (1)), the product mixture was cooled to ambient temperature.

[135] Part B. Acid hydrolysis of mycarosyloxy substituent. Preparation of 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound (3). CH, CH, (2) (3) HBr (48% HBr diluted to 24%) was added to the product mixture of Part A while stirring and maintaining the mixture at less than 40°C. Afterward, the phases in the product mixture were separated using a 20-minute phase separation period. The product mixture was at 20-25°C during this phase separation. HPLC of the lower phase was used to confirm reaction completion (< 2% 20-piperidinyl-tylosin compound (2)).

[136] Part C. Acid hydrolysis of mycinosyloxy substituent. Preparation of 23-Hydroxyl-20-Piperidinyl-5-0-Mycaminosyl-Tylonolide (4). (3) (4) Twenty-four percent HBr (18.4 L) was added at ambient temperature to the aqueous phase obtained from Part B, followed by heating to 54 ± 3°C within about 1 hour while stirring. Stirring was continued at this temperature for 2-4 more hours, while the reaction was monitored using HPLC. After completion of the reaction (< 2% 23-0-mycinosyl-20-piperidinyl-5-O-mycamino syl-tylono lide compound (3)), the mixture was cooled to ambient temperature using a -10°C cooling jacket. After cooling, the mixture was extracted with dichloromethane three times (9.8 kg each time). The aqueous product was cooled to 4-8°C, and then 6 N NaOH (33.6 kg) was slowly added to adjust the pH to >10. The resulting mixture was extracted with dichloromethane three times (with 32.6 kg, 29.3 kg, and 24.5 kg) at ambient temperature. The combined organic phases were charged to a separate reactor. Sodium sulfate (2.9 kg; Na2S04) was added and filtered off. WO 2008/012343 PCT/EP2007/057710 54 Dichloromethane (4.9 kg) was then added and removed via distillation. The resulting crude product was dissolved and re-crystallized twice in tert-butyl methyl ether (6.1 kg each time) at ambient temperature. Afterward, the product was isolated on a Nutsch filter, washed twice with tert-butyl methyl ether (1.0 kg each time), and dried in a tray dryer under vacuum overnight at 40°C. The final product was analyzed using HPLC.

[137] Part D. Iodination. Preparation of activated compound (5). Triphenylphosphine (0.9 kg) and pyridine (0.3 kg; free of water) were dissolved into dichloromethane (11.7 kg) at ambient temperature. Iodine (0.8 kg) was then added. The resulting mixture was then stirred until all the iodine dissolved. The mixture was then cooled to 13°C. The cooled mixture was added to the product from Part C in dichloromethane (11.7 kg) while stirring at 15 ± 3°C. The reaction was monitored by HPLC, and was determined to be completed in 2-2.5 hours (< 2% 23-hydroxyl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound).

[138] Part E. Amination. Preparation of 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide (6). Potassium carbonate (1.8 kg), acetonitrile (16.7 kg), and piperidine (1.1 kg) were added to the product of Part D. The resulting mixture was then heated to 78°C while distilling off dichloromethane. After solvent exchange to acetonitrile, the mixture was stirred at 2-2.5 hours at reflux, and then cooled to ambient temperature. Afterward, the residual potassium carbonate was filtered off, the filter cake was washed with acetonitrile (2.8 kg), and the solvent was distilled off under vacuum at a 50°C jacket temperature. The resulting residue was dissolved in ethyl acetate (15.8 kg), and mixed with 0.5 N HCl (35.6 kg). The (4) (5) (5) (6) WO 2008/012343 PCT/EP2007/057710 55 phases were separated at ambient temperature, and the lower aqueous phase was extracted three times with ethyl acetate (15.8 kg were used each time). The resulting aqueous phase was set to a pH of 11 by addition of 6 N NaOH (6.4 kg) and extracted three times with dichloromethane (18.7 kg each time) at ambient temperature. The combined lower organic phases were recharged to the reactor with sodium sulfate (5.3 kg). The mixture was then filtered to form a cake, which, in turn, was washed with dichloromethane (4.9 kg) and dried under vacuum at a jacket temperature of 50°C to form a macrolide product. This product, in turn, was mixed with acetonitrile (21.7 L) and re-crystallized. The resulting crystals were isolated on a Nutsch filter, washed twice with cold acetonitrile (3.5 L each time), and dried under vacuum at 40°C overnight to form macrolide (5) product. The composition of the product was confirmed using HPLC.

[139] Example 2. Alternative Amination. Preparation of 20,23-Dipiperidinyl-5-O-Mycaminosyl-Tylonolide (2). Potassium carbonate (0.94 kg), xylene (5 L), and piperidine (0.55 kg) are added to 1.0 kg of activated compound (1) made in accordance with the procedure in Part D. The resulting mixture is then heated to 95-105°C for 15 hours. Work-up includes dissolving the K2CO3 in water; removing excess piperidine; extracting into diluted HCl; extracting into tert-butyl methyl ether at a pH of 11; conducting a solvent switch to ethanol; and precipitating, isolating, and drying of the crude product. The product is then re-crystallized from methyl acetate or ethyl acetate. The composition of the product is confirmed using HPLC. (1) (2) WO 2008/012343 PCT/EP2007/057710 56

[140] Example 3. Another illustrative preparation of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide.

[141] Part A. Reductive amination. Preparation of 23-0-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound (2). H3C—o Ox o ~~~Y 9 j ^o oN ^ CH? X Jl /^~TT 3 rw, OH CH; 5 (1) (2) Tylosin phosphate (1) and dichloromethane (1.3 L per kg tylosin phosphate) were charged to a reactor. The resulting mixture was stirred to produce a clear solution. Next, piperidine (1.2 eq, based on the tylosin phosphate), formic acid (4.5 eq, based on the tylosin phosphate), and toluene (6.7 L per kg tylosin phosphate) were sequentially charged 10 to the reactor. The resulting mixture was heated to 76°C while being stirred. Stirring was then continued at that temperature for 2.5 hours. Additional piperidine (0.1 eq, based on the tylosin phosphate) was then charged, and the resulting mixture was stirred at 76°C for an additional hour. The product mixture was cooled to 50°C.

[142] Part B. Acid hydrolysis of mycarosyloxy substituent. Preparation of 15 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide (4). HO H3C^O (3 0 T O—HO CH ' r o' ch3 (2) (4)

[143] Aqueous HBr (23.3 eq, based on the tylosin phosphate used in Part A) was added to the product mixture of Part A at 50°C. The resulting mixture was stirred at 56°C for 5 hours. HPLC was used to monitor the reaction. 20 [144] Once the desired conversion was obtained, the product mixture was cooled. The aqueous phase was extracted twice with dichloromethane at 25-30°C. The aqueous phase was then cooled to 0°C, and the pH was adjusted to 10-10.5 with NaOH at <5°C. Afterward, the aqueous phase was extracted twice with dichloromethane at 20°C. The resulting combined organic phases were extracted twice with aqueous NaHCOs. The 25 dichloromethane was then removed from the combined organic phases via distillation, and WO 2008/012343 PCT/EP2007/057710 57 replaced with isopropyl alcohol. Afterward, heptane at 45°C was added to initiate precipitation. The mixture was then stirred at 0°C. Afterward, the crystalline product was isolated by filtration. The isolated crystals were washed with heptane and isopropyl alcohol, dried, and analyzed using HPLC.

[145] The above procedure made 0.23 kg of product per kilogram of tylosin phosphate used in Part A. This product may contain isopropyl alcohol. To remove the isopropyl alcohol, the product may be dissolved in toluene and dichloromethane, followed by distillation.

[146] Part C. Iodination. Preparation of activated compound (5).

[147] Triphenylphosphine (0.41 kg per kg of product of Part B) was dissolved in dichloromethane (12 L per kg of triphenylphosphine, <100 ppm H2O) at 25°C. Pyridine (0.3 kg per kg triphenylphosphine) was then added. Next, iodine (0.9 kg per kg of triphenylphosphine) was added in 5 portions at 25°C. The resulting mixture was stirred for 40 minutes at 25°C, and then cooled to -6°C. The mixture was then added to the product from Part B over 50 minutes while stirring at -6°C. Afterward, stirring was continued for 7 hours while maintaining the mixture at -5°C. The reaction was monitored by HPLC (if sufficient conversion is not reached, the mixture may be stirred at -5°C for an additional amount of time, e.g., 1.5 hours).

[148] When the desired conversion was reached, the product mixture was washed with aqueous Na2SC>3 solution at -5°C. Dichloromethane was then removed from the organic phase by distillation, and replaced with tetrahydrofuran. (4) (5) WO 2008/012343 PCT/EP2007/057710 58

[149] Part D. Amination. Preparation of 20,23-dipiperidinyl-5-0-mycaminosyl-tylonolide (6). (5) (6)

[150] Piperidine (0.55 kg per kg of product from Part B) was added to the product from Part C, followed by potassium carbonate (0.94 kg per kg of product from Part B). The resulting mixture was heated to 55°C, and then maintained at that temperature for 3 hours while stirring. Afterward, the mixture was heated to 72°C over 1 hour, and then stirred at that temperature for 6 hours. The composition of the product was analyzed using HPLC.

[151] The words "comprise," "comprises," and "comprising" in this patent (including the claims) are to be interpreted inclusively rather than exclusively. This interpretation is intended to be the same as the interpretation that these words are given under United States patent law.

[152] The term "pharmaceutically acceptable" is used adjectivally in this patent to mean that the modified noun is appropriate for use in a pharmaceutical product. When it is used, for example, to describe an excipient or a salt, it characterizes the excipient or salt as having a benefit(s) that outweighs any deleterious effect(s) that the excipient or salt may have to the intended recipient animal.

[153] Unless otherwise characterized by this patent, the term "ambient temperature" means a temperature of from about 20 to about 25°C.

[154] All references cited in this patent are incorporated by reference into this patent.

[155] The above detailed description of preferred embodiments is intended only to acquaint others skilled in the art with the invention, its principles, and its practical application so that others skilled in the art may adapt and apply the invention in its numerous forms, as they may be best suited to the requirements of a particular use. This 'k'k'k'k'k'k'k'k'k </div>

Claims

<div class="application article clearfix printTableText" id="claims"> WO 2008/012343 PCT/EP2007/057710 59 invention, therefore, is not limited to the above embodiments, and may be variously modified. 60 Received at IPONZ 31 August 2011 is claimed is:

1. A process for making a macrolide or a salt thereof, wherein: the macrolide corresponds in structure to Formula (I): r1 r4 ch3 oh (i); the process comprises: reacting tylosin A (or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent to form a 20-piperidinyl-tylosin compound, reacting a 20-piperidinyl-tylosin compound with an acid to form a 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound, reacting a 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound with an acid to form a 23-hydroxyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound, activating a 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound with an activating agent to form an activated compound, and reacting an activated compound with a piperidinyl compound of Formula (VII); the piperidinyl compound of Formula (II) corresponds in structure to: r2 the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III): h (II); WO 2008/012343 PCT/EP2007/057710 61 h3C -(, 6. (HI); the 23 -0-mycinosyl-20-piperidinyl-5 -O-mycaminosyl-tylono lide compound corresponds in structure to Formula (IV): r1 ,r2 H3C-0 6, (IV); the 23 -hydroxyl-20-piperidinyl-5 -O-mycamino syl-tylono lide compound corresponds in structure to Formula (V): ch, (V); the activated compound corresponds in structure to Formula (VI): 62 Received at IPONZ 31 August 2011 the piperidinyl compound of Formula (VII) corresponds in structure to: h R (VII); L is a leaving group; as to R1, R2, and R3: R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen; and as to R4, R5, and R6: R4 and R6 are each methyl, and R5 is hydrogen, R4 and R6 are each hydrogen, and R5 is methyl, or R4, R5, and R6 are each hydrogen.

2. A process of claim 1, wherein at least a portion of the 23-0-mycinosyl-20-piperidinyl-5-O-mycaminosyl-tylonolide compound and at least a portion of the 20-piperidinyl-tylosin compound are reacted with HBr.

3. A process of claim 1, wherein: the process further comprises: reacting tylosin A (or a salt thereof), piperidine, and formic acid in the presence of toluene; reacting the 20-piperidinyl-tylosin compound with HBr; 63 Received at IPONZ 31 August 2011 reacting the 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound with HBr; and activating the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound with an activating agent; the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III-A): O h,c H3C—O' 0. °" ch3 oh °-Hs ch, oh ^ oh ^n 5 Ch3 (III-A); the 23-0-mycinosyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound corresponds in structure to Formula (IV-A): O h3c H3C-o/ Ov 0 ch3 „ oh ch3 (IV-A); the 23-hydroxyl-20-piperidinyl-5-0-mycaminosyl-tylonolide compound corresponds in structure to Formula (V-A): O ^O" ^ OH ch3 (V-A); the activated compound corresponds in structure to Formula (VI-A): 64 Received at IPONZ 31 August 2011 CH3 (VI-A); the activating agent is prepared by a process comprising mixing I2, triphenylphosphine, and pyridine; the piperidinyl compound of Formula (VII) comprises piperidine; and the macrolide corresponds in structure to Formula (I-A): O PTT 3 .N. h3c. ho. n ^ch3 (I-A).

4. A method for treating a disease, wherein the disease is selected from the group consisting of pasteurellosis, swine respiratory disease, and bovine respiratory disease; and the method comprises: preparing a macrolide or pharmaceutically acceptable salt thereof in accordance with any one of claims 1 to 3; and administering a therapeutically effective amount of the macrolide or salt to a non-human animal in need of such treatment.

5. The use of a macrolide or a pharmaceutically acceptable salt thereof prepared in accordance with any one of claims 1 to 3 in the manufacture of a medicament for treating a disease selected from group consisting of pasteurellosis, swine respiratory disease, and bovine respiratory disease. 65 Received at IPONZ 31 August 2011

6. A process for making a 20-piperidinyl-tylosin compound or a salt thereof, wherein: the 20-piperidinyl-tylosin compound corresponds in structure to Formula (III): r1 h,c H3C-0 0. °" ch3 ch, oh CH3 (III); the process comprises reacting tylosin A (or a salt thereof), a piperidinyl compound of Formula (II), and formic acid in the presence of a non-polar solvent; the piperidinyl compound of Formula (II) corresponds in structure to: R r R H (II); and as to R1, R2, and R3: R1 and R3 are each methyl, and R2 is hydrogen, R1 and R3 are each hydrogen, and R2 is methyl, or R1, R2, and R3 are each hydrogen.

7. A process of claim 1 or 6, wherein the non-polar solvent comprises toluene.

8. A process of claim 1, wherein L is iodo.

9. A process of any one of claims 1, 2, 6, or 7, wherein R1, R2 and R3 are each hydrogen. 10. A process of claim 1 or 2, wherein R4, R5, and R6 are each hydrogen. Received at IPONZ 31 August 2011 66

11. A process of claim 1 or 2, wherein R1, R2, R3, R4, R5, and R6 are each hydrogen.

12. A process of claim 1, substantially as herein described with reference to any one of the Examples.

13. A process of claim 6, substantially as herein described with reference to any one of the Examples.

14. A process of any one of claims 1 to 3 or 6 to 11, substantially as herein described.

15. The method of claim 4, substantially as herein described.

16. The use of claim 5, substantially as herein described. </div>